Trial · NCT01421069
Results by group999
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 999
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Malignancy: All Periods of Parent and Extension Study | Etanercept | 1 | Participants | ||
| Number of Participants With Serious Adverse Events: All Periods of Parent and Extension Study | Etanercept | 45 | Participants | ||
| Number of Participants With Serious Infections: All Periods of Parent and Extension Study | Etanercept | 14 | Participants | ||
| Number of Participants With Medically Important Infections: All Periods of Parent and Extension Study | Etanercept | 12 | Participants | ||
| Number of Participants With Infections: All Periods of Parent and Extension Study | Etanercept | 111 | Participants | ||
| Number of Participants With Treatment Emergent Infections and Injection Site Reactions: All Periods of Extension Study | Etanercept | Treatment emergent infections | 67 | Participants | |
| Number of Participants With Treatment Emergent Infections and Injection Site Reactions: All Periods of Extension Study | Etanercept | Injection site reactions | 6 | Participants | |
| Number of Participants With Infections: Extension Study: Withdrawal Period | Etanercept | Infections | 8 | Participants | |
| Number of Participants With Infections: Extension Study: Withdrawal Period | Etanercept | Infections considered preventable by vaccination | 1 | Participants | |
| Number of Participants Withdrawn Due to Adverse Events: All Periods of Parent and Extension Study | Etanercept | Due to infections | 3 | Participants | |
| Number of Participants Withdrawn Due to Adverse Events: All Periods of Parent and Extension Study | Etanercept | Due to other adverse events | 14 | Participants | |
| Number of Participants Withdrawn Due to Adverse Events: Extension Study: Withdrawal Period | Etanercept | 0 | Participants | ||
| Number of Participants With Grade 3 or Grade 4 Laboratory Abnormalities Based on National Cancer Institute Criteria Version 4.03: All Periods of Extension Study | Etanercept | Grade 3 | 2 | Participants | |
| Number of Participants With Grade 3 or Grade 4 Laboratory Abnormalities Based on National Cancer Institute Criteria Version 4.03: All Periods of Extension Study | Etanercept | Grade 4 | 0 | Participants | |
| Change From Baseline of Parent Study in Z-Score at Month 12, 24, 36, 48, 60, 72, 84 and 96 of Extension Study: Active Treatment Period | Etanercept | Change at Month 12 of extension study: Height | 0.22 | Standard Deviation 0.46 | z-score |
| Change From Baseline of Parent Study in Z-Score at Month 12, 24, 36, 48, 60, 72, 84 and 96 of Extension Study: Active Treatment Period | Etanercept | Change at Month 24 of extension study: Height | 0.17 | Standard Deviation 0.56 | z-score |
| Change From Baseline of Parent Study in Z-Score at Month 12, 24, 36, 48, 60, 72, 84 and 96 of Extension Study: Active Treatment Period | Etanercept | Change at Month 36 of extension study: Height | 0.21 | Standard Deviation 0.66 | z-score |
| Change From Baseline of Parent Study in Z-Score at Month 12, 24, 36, 48, 60, 72, 84 and 96 of Extension Study: Active Treatment Period | Etanercept | Change at Month 48 of extension study: Height | 0.19 | Standard Deviation 0.58 | z-score |
| Change From Baseline of Parent Study in Z-Score at Month 12, 24, 36, 48, 60, 72, 84 and 96 of Extension Study: Active Treatment Period | Etanercept | Change at Month 60 of extension study: Height | 0.25 | Standard Deviation 0.67 | z-score |
| Change From Baseline of Parent Study in Z-Score at Month 12, 24, 36, 48, 60, 72, 84 and 96 of Extension Study: Active Treatment Period | Etanercept | Change at Month 72 of extension study: Height | 0.30 | Standard Deviation 0.90 | z-score |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01421069/results